Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
(Created page with "'''Programmed death-ligand 1''', commonly abbreviated '''PD-L1''', is protein with an important role in immune system regulation, and thus cancer aggressiveness. It is a...") |
|||
| Line 2: | Line 2: | ||
It is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref> | It is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref> | ||
PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue = | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref> | |||
*[[Malignant melanoma]]. | |||
*[[non-small cell lung cancer]]. | |||
*[[Renal cell carcinoma]]. | |||
==See also== | ==See also== | ||
Revision as of 03:33, 4 May 2016
Programmed death-ligand 1, commonly abbreviated PD-L1, is protein with an important role in immune system regulation, and thus cancer aggressiveness.
It is also known as CD274.[1]
PD-L1 antibodies are being used to treat:[2]
See also
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 605402
- ↑ Gandini, S.; Massi, D.; Mandalà, M. (Apr 2016). "PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.". Crit Rev Oncol Hematol 100: 88-98. doi:10.1016/j.critrevonc.2016.02.001. PMID 26895815.